Gamida Cell’s proprietary NAM technology is uniquely designed to provide a curative approach to treating a wide range of cancers and genetic diseases.
NAM technology is based on epigenetic regulation by the small molecule, Nicotinamide (NAM), and seeks to overcome challenges associated with expanding cells in a culture while preserving their characteristics and functionality, which typically decrease in culture conditions. This technology addresses these two limitations of ex vivo expansion by:
Gamida Cell has applied NAM technology to develop two of its lead clinical programs by expanding blood forming stem and progenitor cells from umbilical cord blood to create highly functional, stand-alone grafts that serve as a universal bone marrow transplant solution.
Why use cord blood?
Given several limitations associated with bone marrow transplants, Gamida Cell developed its clinical assets using umbilical cord blood, a viable alternative graft source in which:
Current cord blood limitations: The use of standard cord blood for transplantation is limited because a unit of cord blood has a low number of stem and progenitor cells, resulting in delayed engraftment, a higher rate of graft failure, increased morbidity, prolonged hospitalization and higher transplant-related mortality.
Gamida Cell has successfully harnessed its NAM platform technology to leverage the advantages of cord blood and overcome its limitations by increasing the number of CD34+ stem and progenitor cells, while enhancing their homing and engraftment efficiency.
Gamida Cell has robust, cost-effective manufacturing capabilities, applying the proprietary NAM technology to create a large number of functional CD34+ cells for its NiCord® and CordIn™ universal graft modalities.